Differential expression of genes influencing mitotic processes in cord blood mononuclear cells

2 3	after a	pre-conceptional micronutrient-based randomized controlled trial: Pune Rural Intervention in Young Adolescents (PRIYA)
4 5 6	Kunte <sup>3</sup>	eet P. Khare <sup>1,2</sup> #, Ayush Madhok <sup>1</sup> #, Indumathi Patta <sup>1</sup> , Krishna K. Sukla <sup>3</sup> , Vipul V. Wagh <sup>2</sup> , Pooja S. , Deepa Raut <sup>3</sup> , Dattatrey Bhat <sup>3</sup> , Kalyanaraman Kumaran <sup>4</sup> , Caroline Fall <sup>4</sup> , Utpal S. Tatu <sup>5</sup> , Giriraj ndak <sup>6</sup> , Chittaranjan Yajnik <sup>3</sup> *, Sanjeev Galande <sup>1, 7</sup> *
7 8	1.	Indian Institute of Science Education and Research (IISER), Pune, Pashan, Pune, Maharashtra 411008, India
9 10	2.	Symbiosis School of Biological Sciences (SSBS), Symbiosis International (Deemed University), Lavale, Pune, Maharashtra, 412115, India
11	3.	King Edward Memorial Hospital Research Centre, Pune, Maharashtra, 411022, India
12	4.	Medical Research Council Lifecourse Epidemiology Unit, Southampton, UK
13	5.	Indian Institute of Science (IISC), Bangalore, India
14	6.	Centre for Cellular and Molecular Biology (CCMB), Hyderabad, India
15 16	7.	Department of Life Sciences, Shiv Nadar University, Gautam Buddha Nagar, Uttar Pradesh, 201314, India.
17	<sup>#</sup> These	authors contributed equally
18	* For c	orrespondence:
19	<u>csyajni</u>	k@gmail.com
20	<u>sanjee</u>	v@iiserpune.ac.in
21		

- 22 Keywords: Vitamin B12 and micronutrients, randomized controlled trial, cord blood mononuclear
- 23 cells, gene expression profiling, cell cycle, mitotic processes.

24

1

#### 1 Abstract:

2 In the Pune Maternal Nutrition Study, low maternal vitamin B12 and high folate concentrations 3 during pregnancy predicted adiposity and insulin resistance (diabesity) in the children. Based on these findings, we designed an RCT (PRIYA) to provide these nutrients pre-conceptionally to reduce 4 5 diabesity in the offspring. The interventions included: 1) vitamin B12+multi-micronutrients and 6 protein supplement (B12+MMN), 2) vitamin B12 alone, and 3) placebo. A total of 149 women 7 became pregnant and delivered in the trial. We report results of RNA sequencing in the cord-blood 8 mononuclear cells in 88 deliveries. Gene expression analysis revealed 20 differentially expressed 9 genes (FDR <0.1, a discovery threshold) between the B12+MMN and placebo groups. The enriched 10 biological processes included: chromosome segregation, nuclear division and organelle fission. A cell 11 cycle checkpoint gene Claspin (CLSPN) was expressed less in the B12+MMN group but proliferation markers did not differ. No difference was observed between the B12 alone and placebo groups. The 12 13 B-complex vitamins are essential for nucleotide synthesis and generation of S-Adenosyl Methionine, 14 a universal cellular methyl donor and thereby may contribute to the regulation of gene expression. 15 Vitamins A and D, and zinc in MMN may also influence gene expression. We propose that the multimicronutrient intervention influenced rate of progression of specific phases of cell cycle without 16 17 affecting proliferation. Vitamin B12 alone was not sufficient.

18 We highlight a novel molecular mechanism for the effect of multi-micronutrients during fetal 19 development, and a plausible mechanism for intergenerational nutritional programming. Follow up 20 studies will help understand their implications on the future phenotype.

#### 21 Introduction:

The Developmental Origins of Health and Disease (DOHaD) paradigm proposes that the environment during crucial stages of development modifies gene expression through various epigenetic changes which permanently affect the structure and function of an organism (Heindel and Vandenberg, 2015). The DOHaD paradigm was derived from Prof. David Barker's demonstration that lower birth weight (indicative of poor fetal nutrition) was a risk factor for future diabetes and cardiovascular disease (Barker et al., 1989) and suggests a preventable susceptibility factor for these conditions.

28 Methylation of DNA and histones are two epigenetic modifications which influence gene expression 29 (Cedar and Bergman, 2009). Methylation is affected by dietary nutrients which provide or generate 30 methyl groups for cellular metabolism (Switzeny et al., 2012; Kok et al., 2015). These include vitamins B12, folate, B2, B6, choline, betaine, and proteins (Zeisel, 2017). Vitamins A and D are also 31 32 known to influence gene expression through their interaction with the nuclear receptors (Berry et al., 2011; Pasing et al., 2017). Deficiency of these nutrients in the diet of a pregnant mother 33 34 manifests in various developmental defects (neural tube defects, midline congenital defects etc.) and fetal growth abnormalities (growth restriction) (Gernand et al., 2016). Deficiencies of these 35 36 nutrients in early life are also associated with an increased risk of non-communicable diseases in 37 later life (Deshmukh et al., 2013).

The Pune Maternal Nutrition Study (PMNS) is a community based pre-conceptional birth cohort started in 1993. We found that two thirds of the pregnant mothers had low vitamin B12 status but folate status was adequate in the majority (Yajnik et al., 2007). Low maternal B12 status coupled with normal to high folate status was associated with increased diabesity (adiposity and insulin

1 resistance) in the children (Yajnik et al., 2007). Vitamin D deficiency in the mothers was associated 2 with increased adiposity in the children (Wagh et al., 2020). These findings led to the Pune Rural 3 Intervention in Young Adolescents (PRIYA) trial (ISRCTN 32921044 and CTRI 2012/12/003212) (Kumaran et al., 2017). The trial provided vitamin B12 and other micronutrients along with milk 4 5 proteins to the women in the PMNS cohort with a view to reduce the risk of diabesity in their 6 offspring. The PRIYA trial started from the pre-conceptional stage and continued until delivery of the 7 offspring. The trial provided an opportunity to study the effects of maternal micronutrient supplementation on changes in DNA methylation, transcriptome, proteome and metabolome in the 8 9 cord blood of the newborn. In this paper, we report our early findings of cord blood transcriptome 10 analysis in the PRIYA trial.

## 11 Materials and Methods:

## 12 The PRIYA trial

13 PRIYA is a randomized, double blind, placebo-controlled trial in adolescent participants of the PMNS 14 (Figure 1). The rationale and methods of the PRIYA trial are described previously (Kumaran et al., 15 2017). In short, 690 adolescent participants were screened for B12 levels to rule out severe vitamin B12 deficiency (plasma vitamin B12 concentration <100 pmol/L) or severe anaemia (blood 16 hemoglobin concentration <70 gm/L) for ethical imperatives of a placebo controlled trial. Those with 17 chronic medical conditions were also excluded. Eligible participants were randomised into 3 18 supplementation groups: 1) vitamin B12 (2  $\mu$ g/day) along with multi-micronutrients as per 19 UNIMMAP (World Health Organization, 1999), excluding folic acid and conforming to local regulatory 20 21 requirements (Supplementary Table 1), 2) Placebo, 3) vitamin B12 (2  $\mu$ g/day) alone. The multimicronutrient group also received 20 gm of milk powder every day and all 3 groups received iron 22 and folic acid as per Government of India approved dosage (60 mg elemental iron + 500  $\mu$ g folic acid 23 24 once a week before pregnancy and at least 100 tablets during pregnancy). The trial intervention was 25 continued until delivery of the first live child.

26 Monthly supplementation was provided by local field staff, which was in regular touch with the participants. Marriages were recorded and the pregnancies were diagnosed by a urine pregnancy 27 28 test. At 28-weeks' gestation, an obstetric consultation as well as blood tests were performed. The 29 field staff monitored the pregnant women and helped transfer them for delivery at the KEM 30 Hospital, Pune. Trained research staff attended the deliveries and collected cord blood samples as per a standardised protocol. Details of the delivery and baby's measurements were also recorded. A 31 32 cord blood aliquot was transferred to RNAlater (QIAGEN, Germany) tubes and stored at -80°C till 33 further processing.

## 34 Blood measurements

Plasma vitamin B12, holo-TC, folate, vitamin B6, and total homocysteine were measured at baseline (before starting the supplementation), 6-12 months after starting supplementation, at 28 weeks gestation, at delivery, and in the cord blood. Vitamin B2 was also measured at these time-points except at the baseline. Supplementary Table 2 describes the laboratory methods used for these measurements.

40

#### **1** Statistical methods for clinical characteristics:

- 2 The data for maternal and neonatal clinical characteristics is represented as median (IQR). The
- 3 significance of difference between intervention groups was tested by Mann-Whitney test.

## 4 Isolation of cord blood mononuclear cells

- 5 Mononuclear cells from the cord blood were extracted after depleting RBCs from whole blood. In
- 6 brief, batches of frozen blood samples were thawed and diluted with one volume of phosphate
- 7 buffer saline supplemented with EDTA (2mM). One volume of RBC lysis buffer (Biolegend # 420301)
- 8 was added to the diluted samples and incubated for 5 minutes at RT. The tubes were centrifuged at
- 9 350 x g for 15 min at 4°C and the pellets were processed for RNA isolation.

## 10 RNA isolation, sequencing and data analysis

Cord blood mononuclear cells were subjected to RNA isolation using TriZol reagent (Invitrogen). 11 Quantitation of RNA was performed on Qubit 4 Fluorometer (Thermo Scientific #Q33238) using RNA 12 13 HS Kit (Thermo Scientific #Q32852). Libraries were prepared according to the manufacturer's 14 protocol (Illumina). Briefly, each sample was run on 2100 Bioanalyzer (Agilent #G2939BA) to check its integrity. About 500 ng of total RNA from each sample was used to make libraries using TruSeq 15 Stranded mRNA Sample Prep Kit (Illumina #20020594). After final quantification and pooling, the 16 libraries were run on Illumina HiSeqX platform, with 150 nucleotides long paired end reads as the 17 18 output.

19 The raw sequence reads were aligned to the human genome (hg38, Gencode) (Frankish et al., 2019) using HiSAT2 (Kim et al., 2019). The resulting BAM files were used to generate a count matrix using 20 featureCounts for known genes (Liao et al., 2014). The count matrix was used for differential 21 expression analysis using DESeq2 (Love et al., 2014). Since the samples were processed in batches, 22 the batch numbers were used as a covariate. The sex of the child was also used as a covariate. For 23 this discovery analysis we used a p-value adjusted to the FDR of 0.1 as a cut off. The fold change was 24 25 log transformed to the base 2 as per the convention. Significantly differentially expressed genes were subjected to gene enrichment analysis using clusterProfiler (v3.14.3) (Yu et al., 2012). 26

## 27 Results:

# 28 Trial progress and clinical findings:

29 Six hundred and ninety adolescent participants in the PMNS were screened for inclusion in the PRIYA 30 trial (Figure 1). A total of 133 were excluded and 557 (266 girls, 291 boys, average age 17 years) were randomized into 3 groups. A total of 182 girls married, 166 became pregnant and 149 delivered 31 in the study. Cord blood samples were available on 138 for gene expression analysis. This paper 32 33 reports transcriptome measurements on the first 88 cord blood samples (40 girls, 48 boys). These 88 pregnancies were comparable to the 50 who were not included in this study [with respect to 34 35 maternal age, body mass index (BMI), socio-economic status, and hemoglobin concentrations at 28 weeks gestation, p > 0.05]. 36

The mothers were on average 21 years old and weighed 53.0 kgs with a BMI of 22.0 kg/m<sup>2</sup> at 28 weeks gestation (Table 1). Twenty-three mothers delivered by caesarean section. The average birth

1 weight of babies was 2.8 kg (11.3% were low birth weight i.e., <2.5 kg), 3.4% were born pre-term.

2 There was not significant difference in the birth size and pregnancy outcomes in the 3 intervention

3 groups.

At baseline (at 17 years of age) plasma vitamin B12 concentrations were low and 47.7% were B12 deficient (<150 pmol/L), only 1% were folate deficient (<7 nmol/L). Plasma homocysteine concentrations were high, 91% had hyperhomocysteinemia (>15  $\mu$ mol/L). B12, folate and homocysteine concentrations were similar in the 3 intervention groups.

8 Figure 2 shows serial concentrations of vitamin B12, holo-TC ('active' B12), folate and homocysteine 9 during the trial. It can be seen that mothers in the two vitamin B12 supplemented groups had higher 10 vitamin B12 status compared to the placebo group after supplementation; and had lower 11 homocysteine concentrations. Levels of vitamin B2 and B6 were the highest in the B12+MMN group 12 after supplementation (Table 1). Maternal hemoglobin concentrations and other hematological 13 parameters were similar in the 3 groups.

Cord blood concentrations of vitamin B12, holo-TC and folate were higher than the maternal concentrations. Although vitamin B12 and holo-TC were higher in the B12 supplemented groups, the difference from the placebo group was not significant. (Figure 2, Table 1). Cord blood hemoglobin concentration and red cell count were the highest in the group supplemented with B12 alone.

# 18 RNA sequencing and differential gene expression analysis:

Mononuclear cells from 88 cord blood samples were subjected to RNA sequencing. The quality of 19 sequencing was assessed using FastQC (v0.11.8). The guality of sequencing, and read duplication 20 21 levels were acceptable. Each sample generated approximately 50 million reads. The sample reads 22 generally aligned well with the reference genome. Out of the 88 samples, 7 samples showed low 23 alignment (alignment percentage < 70%) against the reference genome and were not considered for 24 the downstream analysis. Our final analysis was therefore, on 81 samples. All samples showed 25 comparable assignment to genes for generation of count matrix. The count matrix was used for 26 differential expression analysis.

Samples showed clear separation based on the sex of the child on principal component analysis (PCA), however, no separation was observed based on laboratory batch or the intervention group (data not shown). No difference in gene expression was observed in the intervention groups based on gender. Differential expression analysis between the B12+MMN group and placebo resulted in identification of 22 differentially expressed genes (Figure 3A) (FDR<0.1) of which 2 were pseudogenes (*AC091057.1* and *DDX11L10*) and were not considered for further analysis (Table 2). The log fold change ranged from -1.6 to 1.0.

To understand the gene-networking of the 20 differentially expression genes (DEGs), we performed analysis using STRING (Szklarczyk et al., 2019). Eighteen of the 20 DEGs were involved in gene networking while *PRSS21* and *FAM72C* were not part of the gene network and segregated separately (Figure 3C). We used clusterProfiler to identify the top biological processes affected by the DEGs (Figure 3B) (Yu et al., 2012). Participants supplemented with B12+MMN showed lower expression of genes associated with mitotic processes such as chromosome segregation, nuclear division, and organelle fission as compared to the placebo group. A cell cycle checkpoint gene, *Claspin (CLSPN)* 

also showed lower expression in the intervention group (Figure 3D). However, cell proliferation
markers such as Cyclin D1 (CCND1), PCNA, and Ki-67 (MKI67) did not show significant differences in
gene expression (data not shown). No differentially expressed genes were observed between
placebo and the B12 alone group; however, the 20 genes differentially expressed between
B12+MMN and placebo were also under expressed in the B12 alone group (Table 2). No significantly
differentially expressed genes were observed between the two active supplementation groups.

#### 7 Discussion:

8 In the present study, we evaluated the effect of maternal pre-conceptional micronutrient 9 intervention on the offspring's cord blood transcriptome. Vitamin B12+MMN intervention resulted 10 in differential expression of 20 genes predominantly influencing mitotic processes such as 11 chromosomal segregation, nuclear division, organelle fission, etc. when compared to placebo. 12 Vitamin B12 alone did not significantly influence the transcriptome compared to the placebo group, 13 though these 20 differentially expressed genes showed a similar trend (under-expression). This is, to 14 our knowledge, the first report of changes in cord blood gene expression after a maternal nutritional intervention started from before conception. The majority of similar studies have only reported 15 16 changes in DNA methylation (Fryer et al., 2011; Cooper et al., 2012; McKay et al., 2012; McCullough 17 et al., 2016).

Nutritional deficiencies are common in the population of villages we have studied. Our intervention 18 19 was based on our findings in earlier studies of substantial vitamin B12 deficiency in the participants and their parents. These villages are drought prone and residents have poor socio-economic status 20 which would contribute to multiple micronutrient deficiencies and poor growth and development in 21 22 babies. Our earlier observations showed that maternal vitamin B12 deficiency during pregnancy, 23 coupled with higher levels of folate predicted higher adiposity and insulin resistance in the children 24 (Yajnik et al., 2007). This prompted us to compare effects of supplementing vitamin B12 alone or in 25 combination with other micronutrients on fetal outcomes. Our intervention showed a demonstrable 26 increase in maternal vitamin B12, holo-TC, B2 and B6 levels in the multi-micronutrient group and of 27 vitamin B12 and holo-TC in the B12 alone group. Though not measured, we would expect better 28 nutrition of vitamins A, D and other micronutrients (vitamin E, Zn etc.) in the MMN group. An 29 impressive fall in maternal homocysteine concentrations in both the active intervention groups 30 (Figure 2) suggests better methylation status. These changes were evident within a few months of 31 starting the supplementation and therefore ensured a better micronutrient status from the pre-32 conceptional stage and during pregnancy. The newborn in the B12+MMN group showed higher 33 concentrations of vitamins B2 and B6, in addition to vitamin B12 and holo-TC, though only B6 was 34 significantly different from placebo (Table 1). Despite significant differences in the maternal 35 circulation, the lack of differences in some of these micronutrients may be due to: alterations in 36 placental transport, differences in binding to carrier proteins, or differential utilisation by the baby 37 (Whitfield et al., 2006; Lager and Powell, 2012). An inspection of the one-carbon (1-C) metabolic 38 cycle (Supplementary Figure 1) and its regulation by B-complex vitamins suggests that babies of 39 mothers who received vitamin B12+MMN would have a more comprehensive effect on purine and 40 pyrimidine synthesis and therefore on DNA and RNA metabolism compared to those who received 41 vitamin B12 alone. Reasons for higher hemoglobin concentration and red blood cell count in the vitamin B12 alone group are not immediately apparent. 42

1 A detailed analysis of our results suggested that of the 20 genes differentially expressed in the 2 vitamin B12+MMN group, 18 clustered in a network which regulates mitotic processes. The affected 3 biological processes include chromosome segregation, nuclear division, organelle fission, etc. These results remind us of the changes described in the bone marrow of patients with pernicious anaemia 4 5 (a severe vitamin B12 deficiency condition which creates a functional folate deficiency and affects 1-6 C metabolism in the direction of reduced methylation potential). The biochemical and morphological 7 changes in pernicious anaemia are suggestive of disturbed DNA synthesis and repair as well as 8 impaired cell division. A recent study on human astrocytes also showed that cobalamin (B12) 9 deficiency impairs DNA synthesis and prolongs G2/M transition leading to cell growth without cell 10 division (Rzepka et al., 2019). 11 We also investigated the expression of standard cell proliferation markers such as cyclin D1,

12 Minichromosome Maintenance Complex Component 2 (MCM2), Proliferating Cell Nuclear Antigen 13 (PCNA) and Ki-67 from the RNA-Seq data (Whitfield et al., 2006). None of these proliferation markers 14 showed a significant change in expression in any intervention group. However, CLSPN, an S-phase 15 checkpoint gene (Liu et al., 2006) showed lower expression in the B12+MMN group as compared to placebo. We propose that a relative deficiency of micronutrients in the placebo group results in a 16 compensatory increase in the expression of genes involved in nucleic acid synthesis and cell division 17 triggered by hypomethylation of the relevant genes. However, micronutrient deficiency 18 19 compromises the supply of nucleotides for DNA synthesis and replication resulting in activation of 20 cell cycle checkpoint. On this background, it appears that genes related to DNA synthesis and cell 21 division were underexpressed in the B12+MMN group because the intervention led to increased 22 micronutrient levels and better methylation status which would promote methylation of the 23 relevant genes.

Our multi-micronutrient composition also included vitamins A and D, and zinc which are known to affect gene expression and cell proliferation in specific tissues (MacDonald, 2000; Blomhoff, 2004; Umar et al., 2018). We speculate that they could presumably contribute to some of our findings of gene expression differences over and above the combined effect of B-complex vitamins in improving cellular methylation potential.

29 Strengths and Limitations: One of the major strengths of our intervention study is that it was guided 30 by earlier nutritional observations in the same cohort. Supplementation in adolescents, much before 31 their marriage and pregnancy made it truly pre-conceptional and had the potential of influencing 32 peri-conceptional epigenetic reprogramming. We used 'physiological' doses of micronutrients, which 33 also makes it public health relevant. The limitations include that these preliminary results are on a 34 relatively small number of cord blood samples which will improve after results on the remaining 35 samples are available. The limited power could also have contributed to a lack of difference in the 36 cord blood measurements between placebo and B12+MMN groups or in body size measurements of 37 the babies in the three groups. Another limitation is that our transcriptomic measurements are 38 limited only to cord blood mononuclear cells which may not reflect changes in other tissues. The 39 specificity of tissue response and temporal changes with gestation can be investigated only in animal 40 models.

41 Our results provide perhaps the first human evidence for molecular effects of pre- and peri-42 conceptional maternal B12+MMN intervention on cord blood. The intervention affected vital cellular

1 processes like cell cycle regulation and cell division during fetal development. These are plausible

2 mechanisms for influencing intrauterine programming. Follow up studies in children will provide an

3 opportunity to investigate the association of these novel alterations to programming of body size

4 and composition, metabolism and neurocognitive function.

## 5 Acknowledgments

6 The work was supported by research grants from Department of Biotechnology (DBT), Government

of India (CEIB-BT/PR12629/MED/97/364/2016) and Indian Council of Medical Research (ICMR) MRC, UK grant (No.58/1/8/ICMR-MRC/2009-NCD-II). The authors thank Drs Ameya Sathe, Ankitha
Shetty for their help in processing cord blood samples, Saurabh Pradhan for help with RNA-seq,

10 Neelam Memane and Rajashree Kamat for laboratory assays, Aboli Bhalerao and Madhura

11 Deshmukh, MSWs and ANMs for their help in the PRIYA study, Mrs. Pallavi Yajnik and Rasika Ladkat 12 for administrative help. AM, IP, and VW thank CSIR-UGC, Government of India for research

13 fellowships. SPK is also a beneficiary of a DST SERB SRG grant (SRG/2020/001414).

# 14 Author contributions

SPK and AM designed the experiments, performed the RNA-Seq analysis and wrote the manuscript. IP assisted in optimization of cell isolation and RNA preparation. KKS, VVW, PSK helped in data analysis and drafting the manuscript. CSY and CF designed the PRIYA trial. KK contributed to running the trial. GRC and UST contributed to the discussion and interpretations. DR and DB assisted in sample collection. SG designed the experiments. CSY and SG discussed and interpreted the results, supported the research, and wrote the manuscript. All authors read and approved the manuscript.

21

1	References:
2 3 4 5	Barker, D. J., Winter, P. D., Osmond, C., Margetts, B., and Simmonds, S. J. (1989). Weight in infancy and death from ischaemic heart disease. <i>Lancet (London, England)</i> 2, 577–580. doi:10.1016/S0140-6736(89)90710-1.
6 7 8	Berry, D. C., Jin, H., Majumdar, A., and Noy, N. (2011). Signaling by vitamin A and retinol-binding protein regulates gene expression to inhibit insulin responses. <i>Proc. Natl. Acad. Sci. U. S. A.</i> 108, 4340–4345. doi:10.1073/PNAS.1011115108.
9	Blomhoff, H. K. (2004). Vitamin A regulates proliferation and apoptosis of human T- and B-cells.
10	Biochem. Soc. Trans. 32, 982–984. doi:10.1042/BST0320982.
11 12	Cedar, H., and Bergman, Y. (2009). Linking DNA methylation and histone modification: patterns and paradigms. <i>Nat. Rev. Genet.</i> 10, 295–304. doi:10.1038/NRG2540.
13	Cooper, W., Khulan, B., Owens, S., Elks, C., Seidel, V., Prentice, A. M., et al. (2012). DNA methylation
14	profiling at imprinted loci after periconceptional micronutrient supplementation in humans:
15	results of a pilot randomized controlled trial. <i>FASEB J</i> . 26, 1782–1790. doi:10.1096/FJ.11-
16	192708.
17	Deshmukh, U., Katre, P., and Yajnik, C. S. (2013). Influence of maternal vitamin B12 and folate on
18	growth and insulin resistance in the offspring. <i>Nestle Nutr. Inst. Workshop Ser</i> . 74, 145–156.
19	doi:10.1159/000348463.
20	Frankish, A., Diekhans, M., Ferreira, A. M., Johnson, R., Jungreis, I., Loveland, J., et al. (2019).
21	GENCODE reference annotation for the human and mouse genomes. <i>Nucleic Acids Res</i> . 47,
22	D766–D773. doi:10.1093/nar/gky955.
23	Fryer, A. A., Emes, R. D., Ismail, K. M., Haworth, K. E., Mein, C., Carroll, W. D., et al. (2011).
24	Quantitative, high-resolution epigenetic profiling of CpG loci identifies associations with cord
25	blood plasma homocysteine and birth weight in humans. <i>Epigenetics</i> 6, 86–94.
26	doi:10.4161/EPI.6.1.13392.
27 28 29	Gernand, A. D., Schulze, K. J., Stewart, C. P., West, K. P., Jr, and Christian, P. (2016). Micronutrient deficiencies in pregnancy worldwide: health effects and prevention. <i>Nat. Rev. Endocrinol.</i> 12, 274. doi:10.1038/NRENDO.2016.37.
30	Heindel, J. J., and Vandenberg, L. N. (2015). Developmental Origins of Health and Disease: A
31	Paradigm for Understanding Disease Etiology and Prevention. <i>Curr. Opin. Pediatr.</i> 27, 248.
32	doi:10.1097/MOP.000000000000191.
33	Kim, D., Paggi, J. M., Park, C., Bennett, C., and Salzberg, S. L. (2019). Graph-based genome alignment
34	and genotyping with HISAT2 and HISAT-genotype. <i>Nat. Biotechnol.</i> 37, 907–915.
35	doi:10.1038/s41587-019-0201-4.
36	Kok, D. E., Dhonukshe-Rutten, R. A., Lute, C., Heil, S. G., Uitterlinden, A. G., van der Velde, N., et al.
37	(2015). The effects of long-term daily folic acid and vitamin B 12 supplementation on genome-
38	wide DNA methylation in elderly subjects. <i>Clin. Epigenetics 2015 71</i> 7, 1–14.
39	doi:10.1186/S13148-015-0154-5.
40	Kumaran, K., Yajnik, P., Lubree, H., Joglekar, C., Bhat, D., Katre, P., et al. (2017). The Pune Rural
41	Intervention in Young Adolescents (PRIYA) study: design and methods of a randomised
42	controlled trial. <i>BMC Nutr</i> . 3. doi:10.1186/S40795-017-0143-5.

1 2	Lager, S., and Powell, T. L. (2012). Regulation of nutrient transport across the placenta. <i>J. Pregnancy</i> 2012. doi:10.1155/2012/179827.
3 4 5	Liao, Y., Smyth, G. K., and Shi, W. (2014). FeatureCounts: An efficient general purpose program for assigning sequence reads to genomic features. <i>Bioinformatics</i> 30, 923–930. doi:10.1093/bioinformatics/btt656.
6	Liu, S., Bekker-Jensen, S., Mailand, N., Lukas, C., Bartek, J., and Lukas, J. (2006). Claspin Operates
7	Downstream of TopBP1 To Direct ATR Signaling towards Chk1 Activation. <i>Mol. Cell. Biol.</i> 26,
8	6056. doi:10.1128/MCB.00492-06.
9 10	Love, M. I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. <i>Genome Biol.</i> 15, 550. doi:10.1186/s13059-014-0550-8.
11	MacDonald, R. S. (2000). The role of zinc in growth and cell proliferation. <i>J. Nutr.</i> 130.
12	doi:10.1093/JN/130.5.1500S.
13	McCullough, L. E., Miller, E. E., Mendez, M. A., Murtha, A. P., Murphy, S. K., and Hoyo, C. (2016).
14	Maternal B vitamins: effects on offspring weight and DNA methylation at genomically
15	imprinted domains. <i>Clin. Epigenetics</i> 8, 1–11. doi:10.1186/S13148-016-0174-9.
16	McKay, J. A., Groom, A., Potter, C., Coneyworth, L. J., Ford, D., Mathers, J. C., et al. (2012). Genetic
17	and non-genetic influences during pregnancy on infant global and site specific DNA
18	methylation: role for folate gene variants and vitamin B12. <i>PLoS One</i> 7.
19	doi:10.1371/JOURNAL.PONE.0033290.
20	Pasing, Y., Fenton, C. G., Jorde, R., and Paulssen, R. H. (2017). Changes in the human transcriptome
21	upon vitamin D supplementation. <i>J. Steroid Biochem. Mol. Biol.</i> 173, 93–99.
22	doi:10.1016/J.JSBMB.2017.03.016.
23	Rzepka, Z., Rok, J., Respondek, M., Pawlik, J., Beberok, A., Gryko, D., et al. (2019). Cobalamin
24	Deficiency: Effect on Homeostasis of Cultured Human Astrocytes. <i>Cells</i> 8.
25	doi:10.3390/CELLS8121505.
26	Switzeny, O. J., Müllner, E., Wagner, K. H., Brath, H., Aumüller, E., and Haslberger, A. G. (2012).
27	Vitamin and antioxidant rich diet increases MLH1 promoter DNA methylation in DMT2 subjects.
28	<i>Clin. Epigenetics 2012 41</i> 4, 1–11. doi:10.1186/1868-7083-4-19.
29	Szklarczyk, D., Gable, A. L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., et al. (2019). STRING v11:
30	protein-protein association networks with increased coverage, supporting functional discovery
31	in genome-wide experimental datasets. <i>Nucleic Acids Res.</i> 47, D607–D613.
32	doi:10.1093/NAR/GKY1131.
33	Umar, M., Sastry, K., and Chouchane, A. (2018). Role of Vitamin D Beyond the Skeletal Function: A
34	Review of the Molecular and Clinical Studies. <i>Int. J. Mol. Sci.</i> 19, 1618.
35	doi:10.3390/IJMS19061618.
36	Wagh, R. H., Bawdekar, R. U., Alenaini, W., Fall, C. H. D., Thomas, E. L., Bell, J. D., et al. (2020).
37	Maternal Micronutrient Status in Pregnancy is Associated with Child's Adiposity at 18yrs of age.
38	in (Journal of Developmental Origins of Health and Disease). doi:10.1017/S2040174419000643.
39 40	Whitfield, M. L., George, L. K., Grant, G. D., and Perou, C. M. (2006). Common markers of proliferation. <i>Nat. Rev. Cancer</i> 6, 99–106. doi:10.1038/NRC1802.
41	World Health Organization (1999). Composition of a multi-micronutrient supplement to be used in

- 1 pilot programmes among pregnant women in developing countries: report of a United Nations
- 2 Children's Fund (UNICEF), World Health Organization (WHO) and United Nations University
- 3 workshop. Available at: https://apps.who.int/iris/handle/10665/75358.
- 4 Yajnik, C. S., Deshpande, S. S., Jackson, A. A., Refsum, H., Rao, S., Fisher, D. J., et al. (2007). Vitamin
- 5 B12 and folate concentrations during pregnancy and insulin resistance in the offspring: the
- 6 Pune Maternal Nutrition Study. *Diabetologia* 51, 29–38. doi:10.1007/s00125-007-0793-y.
- Yu, G., Wang, L. G., Han, Y., and He, Q. Y. (2012). clusterProfiler: an R package for comparing
   biological themes among gene clusters. *OMICS* 16, 284–7. doi:10.1089/omi.2011.0118.
- 9 Zeisel, S. (2017). Choline, Other Methyl-Donors and Epigenetics. *Nutrients* 9.
- 10 doi:10.3390/NU9050445.
- 11 1.

# 1 Table 1: Comparison of clinical characteristics between study participants of 3 intervention groups

	1	Maternal chara		1	1	
	B12+MMN group : Median (IQR)	Placebo group : Median (IQR) (N=29)	B12 alone group : Median (IQR) (N=30)	P-value (B12+ MMN Vs	P-value (Placebo Vs B12	P-value (B12+MMN Vs B12
	(N=29)			Placebo)	alone)	alone)
Anthropometry		28 weeks	gestation			
Age (Years)	21.2 (2.4)	21.3 (2.0)	21.1 (1.9)	0.578	0.773	0.781
BMI (kg/m²)	21.5 (2.5)	21.7 (3.5)	20.8 (3.7)	0.975	0.176	0.080
	1	Baseline (17	-	1		
Hemoglobin (g/dL)	12.8 (1.8)	12.7 (2.0)	12.7 (1.5)	0.474	0.738	0.268
Vitamin B12 (pmol/L)	160.0 (87.0)	147.0 (46.0)	148.5 (63.0)	0.131	0.439	0.544
Holo-TC (pmol/L)	13.0 (8.8)	10.1 (4.3)	10.2 (8.1)	0.096	0.934	0.145
Folate (nmol/L)	15.5 (13.5)	21.7 (11.2)	17.0 (14.6)	0.029	0.117	0.471
Homocysteine	21.0(11.1)	24.2 (21.8)	22.8 (10.7)	0.539	0.328	0.897
		Post-intervention	(18 Years)			
Hemoglobin (g/dL)	12.0(1.6)	12.0 (1.6)	11.7 (1.2)	1.000	0.219	0.179
Vitamin B12 (pmol/L)	262.0 (122.1)	161.9 (69.0)	272.5 (165.9)	0.000	0.000	0.246
Holo-TC (pmol/L)	23.6 (24.1)	8.9 (5.6)	28.8 (27.7)	0.000	0.000	0.295
Folate (nmol/L)	19.4 (11.9)	24.9 (19.8)	23.0 (14.8)	0.030	0.222	0.375
Homocysteine (µmol/L)	10.0 (4.5)	24.3 (19.8)	10.6 (4.1)	0.000	0.000	0.850
		28 weeks ges	station			
Hemoglobin (g/dL)	10.4 (1.7)	10.6 (1.6)	10.4 (1.9)	0.635	0.595	0.946
Vitamin B12 (pmol/L)	202.0 (121.0)	153.0 (109.0)	216.5 (180.5)	0.015	0.002	0.292
Holo-TC (pmol/L)	29.4 (29.8)	16.6 (14.6)	35.3 (50.2)	0.009	0.005	0.606
Folate (nmol/L)	42.1 (41.9)	45.6 (34.3)	48.3 (35.3)	0.497	0.850	0.655
Vitamin B2 (pmol/L)	240.0 (79.0)	226.0 (48.0)	224.0 (64.0)	0.351	0.586	0.202
Vitamin B6 (plp) (µg/ml)	4.9 (3.4)	3.6 (3.2)	3.2 (1.7)	0.010	0.720	0.000
Vitamin B6 (pyx) (µg/ml)	1.6 (1.2)	1.2 (0.7)	1.2 (0.5)	0.127	0.913	0.042
Homocysteine (µmoles/L)	6.6 (3.5)	6.6 (4.0)	6.2 (3.6)	0.339	0.252	0.952
		At delive	ry			
Vitamin B12 (pmol/L)	176.0 (80.0)	159.0 (101.0)	205.0 (90.5)	0.144	0.033	0.461
Holo-TC (pmol/L)	28.1 (29.5)	24.6 (22.5)	31.2 (45.6)	0.312	0.075	0.359
Folate (nmol/L)	30.1 (40.6)	43.5 (49.7)	33.6 (53.0)	0.576	0.805	0.988
Homocysteine (µmole/L)	7.8 (8.0)	8.9 (4.2)	8.6 (3.8)	0.307	0.324	0.852
		Neonatal chara	cteristics			
Anthropometry						
Birth weight (gms)	2951 (564)	2760 (310)	2778 (388)	0.305	0.601	0.083
Birth lengh (cm)	48.2 (2.4)	48.4 (1.8)	48.5 (1.9)	0.597	0.426	0.850
		Cord blood bioch	emistry			
Vitamin B12 (pmol/L)	292.0 (226.0)	282.0 (301.0)	380.5 (442.2)	0.858	0.108	0.154
Holo-TC (pmol/L)	94.7 (94.2)	61.3 (89.2)	121.7 (71.2)	0.634	0.164	0.301
Folate (nmol/L)	47.6 (27.9)	56.9 (35.8)	55.5 (33.1)	0.413	0.671	0.562

Vitamin B2 (pmol/L)	321.0 (100.0)	289.0 (78.0)	304.0 (82.0)	0.401	0.476	0.909		
Vitamin B6 (plp) (µg/ml)	32.3 (15.1)	23.4 (19.9)	23.5 (16.2)	0.034	0.622	0.059		
Vitamin B6 (pyx) (µg/ml)	5.2 (2.6)	4.1 (1.4)	4.8 (2.7)	0.014	0.154	0.271		
Homocysteine (µmole/L)	6.9 (5.0)	7.1 (5.9)	5.6 (3.4)	0.602	0.059	0.143		
Cord blood hematology								
Hemoglobin (g/dL)         13.9 (1.4)         13.6 (2.2)         14.8 (1.5)         0.774         0.038         0.048								
White blood cell count (*10^3/uL)	14.2 (3.5)	14.9 (6.9)	12.9 (6.7)	0.719	0.332	0.493		
Red blood cell count (*10^6/uL)	4.0 (0.6)	3.9 (0.5)	4.4 (0.6)	0.798	0.008	0.036		
Platelet count (*10^3/uL)	272.5 (62.8)	270.0 (78.0)	245.0 (85.5)	0.439	0.321	0.054		

1 Note: IQR: Inter Quartile Range, plp: pyridoxal 5<sup>D</sup>-phosphate, pyx: pyridoxine ; values represent

2 median (IQR); P-values calculated by Mann-Whitey test.

- 1 Table 2: List of differentially expressed genes in the two intervention groups (B12+MMN and B12
- 2 alone) with respect to the placebo.

	Gene name	Chromosom al location	Placebo vs B12+MMN		Placebo vs B12		
Gene			log2 FoldCh ange	padj	log2 FoldCh ange	padj	Function
KIF14	kinesin family member 14	1q32.1	-1.069	0.073	-0.589	1	Cell division
CENPF	centromere protein F	1q41	-1.045	0.073	-0.629	1	Tubulin binding
KIF15	kinesin family member 15	3p21.31	-1.049	0.073	-0.544	1	Microtubule binding
NCAPG	non-SMC condensin I complex subunit G	4p15.31	-1.132	0.073	-0.609	1	Chromosome segregation
KIFC1	kinesin family member C1	6p21.32	-1.153	0.073	-0.672	1	Mitotic cell cycle
ESCO2	establishment of sister chromatid cohesion N- acetyltransfera se 2	8p21.1	-1.21	0.073	-0.636	1	Chromosome segregation
РВК	PDZ binding kinase	8p21.1	-1.656	0.073	-0.668	1	Mitotic cell cycle (regulation of protein kinase activity)
AC091057 .1	NA		-0.92	0.073	-0.313	1	Pseudogene
KNL1	kinetochore scaffold 1	15q15.1	-1.12	0.073	-0.649	1	Chromosome segregation
PRSS21	serine protease 21	16p13.3	-1.101	0.073	-0.77	1	Regulation of testicular germ cell maturation
TUBG1	tubulin gamma 1	17q21.31	-0.894	0.073	-0.79	0.89	Major constituent of microtubules
FAM72B	family with	1p11.2	-1.045	0.073	-0.787	1	Cell growth

	sequence similarity 72 member B						regulation
FAM72C	family with sequence similarity 72 member C	1q21.1	-1.066	0.077	-0.75	1	Cell growth regulation
DDX11L10	DEAD/H-box helicase 11 like 10 (pseudogene)	16p13.3	1.089	0.082	0.016	1	Pseudogene
SHCBP1	SHC binding and spindle associated 1	16q11.2	-0.985	0.082	-0.658	1	Spermatogene sis
CLSPN	claspin	1p34.3	-0.96	0.089	-0.644	1	Anaphase- promoting complex binding
CCNA2	cyclin A2	4q27	-1.015	0.093	-0.598	1	Mitotic cell cycle
CDKN3	cyclin dependent kinase inhibitor 3	14q22.2	-1.052	0.093	-0.357	1	Mitotic cell cycle phase transition
PLK1	polo like kinase 1	16p12.2	-1.155	0.093	-0.815	1	Microtubule binding
SKA1	spindle and kinetochore associated complex subunit 1	18q21.1	-1.313	0.093	-0.825	1	Chromosome segregation
NCAPG2	non-SMC condensin II complex subunit G2	7q36.3	-0.74	0.099	-0.428	1	Chromosome segregation
DEPDC1	DEP domain containing 1	1p31.3	-1.179	0.099	-0.54	1	Transcriptional regulation as a transcriptional co-repressor

1 Figure legends:

Figure 1: The Pune Maternal Nutrition Study (PMNS) and the Pune Rural Intervention in Young
 Adolescents (PRIYA) trial. A) Broad plan of the study. B) CONSORT diagram of the PRIYA trial.

4 Figure 2: Serial micronutrient levels in PRIYA trial. Median concentrations of A) vitamin B12

5 (pmol/L), B) Holo-TC (pmol/L), C) folate (nmol/L), and D) total homocysteine ( $\mu$ mol/L) at baseline (17

6 years of age), post-intervention (18 years of age; 6-12 months after starting supplementations), 28

7 weeks gestation and at delivery in the mothers, and in the cord blood of the baby. P-value denotes

8 significance of difference from the placebo, using the Mann-Whitney test; MMN, multiple

- 9 micronutrients.
- 10 Figure 3: Gene enrichment analysis of genes differentially expressed between B12+MMN group

11 and placebo. A) Volcano plot, B) Gene enrichment analysis, C) Clustering analysis of the top 20

12 differentially expressed genes, and D) Expression plot of CLSPN, a negative regulator of cell cycle

13 progression, in the three intervention groups; MMN, multiple micronutrients.

Figure 1






Figure 2



# Figure 3

А



В



